Jan 08, 2025
Myeloid Therapeutics to Present at 43rd Annual JP Morgan Healthcare Conference
Nov 13, 2024
Myeloid Therapeutics to Participate in Jefferies London Healthcare Conference
Aug 29, 2024
Myeloid Therapeutics to Participate in Upcoming Investor Conferences
Jul 31, 2024
Myeloid Therapeutics Initiates Patient Dosing with MT-303, a Novel GPC3 Targeting RNA CAR, in Phase 1 Study for Advanced Hepatocellular Carcinoma (HCC)
May 30, 2024
Myeloid Therapeutics to Participate in the Jefferies Healthcare Conference Private Biotech Day
May 07, 2024
Myeloid Therapeutics Presents Multiple Posters at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
May 07, 2024
Myeloid Therapeutics Presents Multiple Posters at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
Apr 04, 2024
Myeloid Therapeutics to Showcase In Vivo CAR Data and its Diverse mRNA Platform at AACR
Mar 05, 2024
Myeloid Therapeutics to Provide Updates on its RNA Immunotherapies at Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024
Feb 01, 2024
Myeloid Expands Leadership Team with Robert Hofmeister, Ph.D., as Chief Scientific Officer
Jan 05, 2024
Prime Medicine and Myeloid Therapeutics Announce Settlement of Pending Disputes
Jan 11, 2021
Myeloid Therapeutics and MaxCyte Enter Clinical and Commercial Licensing Agreement to Advance Myeloid's Cell Therapy Programs
Jan 06, 2021
Myeloid Therapeutics Launches with Over $50 Million in Financing and Two Clinical Trials